C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein , Germany . As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies , and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases , metabolism , immunology , oncology and diseases of the central nervous system . Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations ( EFPIA ). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne .
30-804: The Erwin Schrödinger Prize (German: Erwin Schrödinger-Preis ) is an annual award presented by the Austrian Academy of Sciences for lifetime achievement by Austrians in the fields of mathematics and natural sciences . The prize was established in 1958, and was first awarded to its namesake, Erwin Schrödinger . The prize is awarded at the discretion of the Austrian Academy of Sciences to scholars resident in Austria for excellence and achievements in
60-596: A "qui tam" (whistleblower) case with the U.S. government for $ 95 million alleging "off-label" marketing of the drugs Aggrenox, Atrovent, Combivent, and Micardis for uses that weren't approved by the US Food and Drug Administration and were not covered by federal health care programs. In August 2012, Pradaxa claims filed in the federal court were consolidated in a multi-district litigation in the Southern District of Illinois before Chief Judge David R. Herndon. On 28 May 2014,
90-419: A $ 650 million settlement was announced on behalf of approximately 3,900 claimants who were injured by the drug Pradaxa made by Boehringer Ingelheim Pharmaceuticals, Inc. The drug is alleged to cause severe bleeding events and/or hemorrhaging to those who were taking the drug. In October 2023 Boehringer Ingelheim was ordered to pay a 10 million Euro fine for illegal price fixing that had gone on globally over
120-525: A checkpoint inhibitor antibody designed to treat solid tumors. In the same month Boehringer announced a partnership with Topas Therapeutics and their virus-based vectors. In mid-September the company exercised its option to acquire viral cancer therapy developer, ViraTherapeutics , for €210 million ($ 245 million). In March 2019, Boehringer announced it would acquire ICD Therapeutics. In July, subsidiary company Boehringer Ingelheim Pharmaceuticals, Inc. announced it had acquired Amal Therapeutics SA, boostings
150-463: A developer of oncolytic virus therapies, dependent on the success of Phase I trials. In June 2016, the company announced it had struck an asset-swap deal with Sanofi , Boehringer would sell its consumer health division (valuing it at €6.7 billion) and €4.7 billion in cash, whilst acquiring the Merial animal health division (valuing it at €11.4 billion / $ 12.4 billion). The deal could mean that Boehringer
180-494: A division of Boehringer Ingelheim, voluntarily shut down after a U.S. Food and Drug Administration inspectors' report that found the plant had rusty tools, mold, and a barrel of 'unknown liquid', later found to be urine . The company invested US$ 300,000,000 to upgrade the drug manufacturing plant, and limited production resumed in October 2012. However, on 3 October 2013, Ben Venue announced that it would be ceasing production by
210-698: A legal entity under the special protection of the Republic of Austria. According to the statutes of the Academy its mission is to promote the sciences and humanities in every respect and in every field, particularly in fundamental research. In 1713, Gottfried Wilhelm Leibniz suggested to establish an Academy, inspired by the Royal Society and the French Academy of Sciences . The "Kaiserliche Akademie der Wissenschaften in Wien"
240-804: A newly established Quantum Lab of Boehringer Ingelheim. Boehringer Ingelheim is also a founding member of the Quantum Technology and Application Consortium (QUTAC). Prescription Medicines: Consumer Health Care (sold to Sanofi ): Animal Health: Also in companion animal portfolio: Purevax feline vaccines, Recombitek canine vaccine, Imrab rabies vaccine, NexGard (afoxolaner), NexGard Spectra (afoxolaner/milbemycin oxime), NexGard Combo ( esafoxolaner/eprinomectin/praziquantel ), Heartgard-30 Plus (ivermectin/pyrantel pamoate), Immiticide (melarsomine), Senvelgo (velagliflozin) Boehringer Ingelheim's product pipeline targets lung disease , cancer , and hepatitis C . In October 2012 Boehringer Ingelheim settled
270-409: A period of nearly fifteen years. Boehringer bears the largest share of an antitrust fine totaling € 13.4 million. Anyone affected by its anti-competitive behavior may claim damages, competition regulators stressed. As a private company, Boehringer Ingelheim (BI) is not required to disclose detailed financial information publicly; the owners have considered an IPO and ruled it out. In 2006,
300-407: A treatment being used in early trials against triple-negative breast cancer and lung cancer , for $ 1.5 billion. In June 2020, Boehringer and G1 Therapeutics announced a co-promotion agreement for trilaciclib (Cosela) , a CDK4/6 inhibitor designed to prevent chemotherapy-induced myelosuppression . The agreement targets small cell lung cancer , will initially run for three years, and covers
330-601: Is a globally operating company, with 146 subsidiaries around the globe. The company's largest site and corporate headquarters is in Ingelheim am Rhein near Mainz and Frankfurt, Germany. Their main business regions are Europe, North America and Asia. The Research Institute of Molecular Pathology in Vienna (Austria), founded in 1985, has had Boehringer Ingelheim as its main sponsor since 1993. In 2011, Ben Venue Laboratories in Bedford, Ohio ,
SECTION 10
#1732876974984360-433: Is now one of the animal healthcare global leaders. In September of the same year, Amgen announced it would purchase the rights to Boehringer Ingelheims Phase I bispecific T-cell engager compound ( BI 836909 , now AMG 420) for use in the treatment of multiple myeloma . As part of the asset swap, Boehringer and Merial sold a number of assets to Ceva Santé Animale - namely some animal health vaccines and pharmaceuticals from
390-696: The Acoustics Research Institute , the Space Research Institute and the Institute for High Energy Physics (HEPHY), Wien . During his term as president of the academy (1991–2003), Werner Welzig initiated the establishment of the Galerie der Forschung (English: Gallery of Research). In 2005 the Gallery organised its pilot event "Mapping controversies: the case of the genetically modified food", which
420-514: The European Commission . On January 11, 2021, Boehringer Ingelheim announced a collaborative agreement with Google Quantum AI (Google), focusing on researching and implementing cutting-edge use cases for quantum computing in pharmaceutical research and development (R&D), specifically including molecular dynamics simulations. Boehringer Ingelheim is the first pharmaceutical company worldwide to join forces with Google in quantum computing in
450-753: The Institute of Molecular Biotechnology (which is operated in cooperation with Boehringer Ingelheim ), the Gregor Mendel Institute , the Aithyra Institute for biomedical Artificial Intelligence, the Johann Radon Institute for Computational and Applied Mathematics (RICAM), Linz , the Research Center for Molecular Medicine , the Erich Schmid Institute of Materials Science , the Institute for Quantum Optics and Quantum Information ,
480-1213: The United States and Puerto Rico . In September 2021, the company announced it would acquire Abexxa Biologics, boosting its cancer immunotherapy research. In 2023, the World Intellectual Property Organization (WIPO) ’s Madrid Yearly Review ranked Boehringer's number of marks applications filled under the Madrid System as 4th in the world, with 118 trademarks applications submitted during 2023. Boehringer Ingelheim works in human pharmaceuticals , animal health , and biopharmaceuticals . The group consists of 145 affiliated companies with around 50,000 employees in 2017 in all continents. Research and development facilities were in five sites and 20 production plants in 13 countries. The research and development facilities are located in Biberach (Germany), Ridgefield (Connecticut), Vienna , Kobe , and Milan (closed in 2017). Over 8,000 employees work for Boehringer Ingelheim in research and development. Boehringer Ingelheim
510-462: The Academy of Knowledge. Mathematical and natural science class (Denkschriften der Akademie der Wissenschaften), which was founded in 1850. Boehringer Ingelheim The company supplied the most potent ingredient of Agent Orange . In 2004, the company acquired STEAG microParts GmbH. In December of the same year the company announced the acquisition of the outstanding shares of Boehringer Ingelheim Shionogi Vetmedica. In June 2008,
540-578: The Merial portfolio for swine, bovine and companion animals, as well as some intellectual property, manufacturing processes and R&D activities. In October 2016 the company sold its US pet vaccines business and a manufacturing plant for $ 885 million, to Eli Lilly's Elanco Animal Health division. In April 2018, the company announced that it would launch an immuno-oncology partnership with OSE Immunotherapeutics worth up-to-$ 1.4 billion, focussing on developing OSE's late-preclinical-stage candidate OSE-172 ,
570-669: The Nobel Prize winners Julius Wagner-Jauregg , Victor Francis Hess , Erwin Schrödinger and Konrad Lorenz . Anton Zeilinger , predecessor of the academy's incumbent president, is Nobel Prize laureate in physics 2022. The academy operates 25 research institutes. In 2012, a reorganization prompted the outsourcing of various institutes to universities as well as mergers. The academy's institutes are split into two major divisions, one for mathematics and natural sciences ( mathematisch-naturwissenschaftliche Klasse ) and one for humanities and social sciences ( philosophisch-historische Klasse ). In
600-844: The business' focus on cancer immunotherapy and vaccine treatments. In May 2020, the business announced it would acquire Northern Biologics Inc. which focuses on therapeutic antibodies targeting tumours. In June, the business announced it would sell off part of its stake in London-listed Hikma Pharmaceuticals (28 million out of a 40 million share holding) for around $ 800 million. In July, the company announced it would acquire Global Stem cell Technology, boosting its animal health business. In December, Boehringer announced it would acquire Labor Dr. Merk & Kollegen, boosting its immuno-oncology therapy range including Vesicular Stomatitis Virus and cancer vaccines platforms and Swiss-based NBE Therapeutics, adding drug candidates including
630-471: The company acquired FX125L and the somatotaxin programme from Funxional Therapeutics for an undisclosed sum. In May 2015, the company acquired the investigational drug PXS4728A from Pharmaxis ’. In July, the company sold its Roxane business to Hikma Pharmaceuticals Plc for $ 2.65 billion ($ 1.18 billion in cash and issue 40 million new Hikma shares). The company also agreed to make cash payments of up to $ 125 million based on performance milestones. On
SECTION 20
#1732876974984660-625: The company announced its intention to acquire Actimis Pharmaceuticals for $ 515 million, depending on the performance of Actimis' leading asthma compound AP768. In 2009, through its US subsidiary, Boehringer Ingelheim Vetmedica Inc., acquired a significant portion of the Fort Dodge Animal Health business from Pfizer . In 2010, BI, through its Boehringer Ingelheim Japan Investment GK subsidiary, acquired all outstanding shares of SSP CO., Ltd, with Nippon Boehringer Ingelheim Co., Ltd already holding 60.2% of SSP CO's shares. In August 2012,
690-434: The company sold the commercialisation rights to BI 655066 ( Risankizumab ), to AbbVie for $ 595 million upfront as well as undisclosed milestone payments and royalties. BI 655066 is a drug in late-stage testing for psoriasis , and in earlier testing for Crohn's disease , psoriatic arthritis and asthma . In September of the same year the company announced it would acquire ViraTherapeutics for €210 million ($ 230 million ),
720-569: The end of 2013 due to being unable to "return to sustainable production." Boehringer Ingelheim is involved in publicly funded collaborative research projects with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox . The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and
750-807: The field of humanities , there are the Institute for the Study of Ancient Culture , which is well known for the analysis of excavation results in Carnuntum and Ephesos , the Institute for Interdisciplinary Mountain Research , focusing on montology , the Institute of Culture Studies and Theatre History , and the Vienna Institute of Demography , among others. The academy conducts socio-cultural research in Tibetan-speaking Himalayas, Tibet, and central Asia. Facilities that focus on natural sciences include
780-401: The mathematical and scientific disciplines in the broadest sense. The prize is not awarded to full members of the Academy. The award ceremony is held annually in October. The prize includes an annual stipend currently of € 15 000, paid monthly. Source: Austrian Academy of Sciences The Austrian Academy of Sciences (German: Österreichische Akademie der Wissenschaften ; ÖAW ) is
810-417: The mid-1960s onwards it became the country's leading institution in the field of non-university basic research. The academy is also a learned society , and its past members have included Theodor Billroth , Ludwig Boltzmann , Christian Doppler , Anton Eiselsberg , Otto Hittmair , Paul Kretschmer , Hans Horst Meyer , Albert Anton von Muchar , Julius von Schlosser , Roland Scholl , Eduard Suess and
840-419: The same day the company announced it would partner with Hanmi Pharmaceutical to develop and commercialise HM61713 , a third generation treatment for EGFR mutation-positive lung cancer . Boehringer also terminated its collaboration with Vitae Pharmaceuticals on a new BACE program for Alzheimer's. The company sold the rights to Faldaprevir , a HCV protease inhibitor to Trek Therapeutics. In July 2016,
870-401: Was finally established by Imperial Patent on 14 May 1847. The academy soon began extensive research. In the humanities the academy started with researching and publishing important historical sources of Austria. Research in natural science also covered a wide variety of topics. The 1921 federal law guaranteed the legal basis of the academy in the newly founded First Austrian Republic . From
900-638: Was staged in the Alte Aula in Vienna. Via its Austrian Academy of Sciences Press imprint, the academy publishes Medieval Worlds: Comparative & Interdisciplinary Studies , a biannual peer-reviewed open access academic journal covering Medieval studies . Other publications are the Corpus Scriptorum Ecclesiasticorum Latinorum and eco.mont – Journal on Protected Mountain Areas Research and Management . Also Memoranda of
#983016